Pharm prime vendor fleet
Ended Awarded Last action
- Contract number
- SPE2DU26F0V17
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,758
Award facts
- Contract value 100% obligated
- $1,757.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $1,757.57, was awarded on February 3, 2026, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. The award was issued by the Defense Logistics Agency under a firm fixed-price delivery order structure with an ultimate completion date of February 4, 2026. DMS Pharmaceutical Group Inc. operates without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The company specializes in distributing comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations, including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and over-the-counter drugs.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, was awarded on November 13, 2025, and positions DMS Pharmaceutical Group as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program enables the Defense Logistics Agency to issue delivery orders for pharmaceutical products supporting recurring medical supply needs of military healthcare facilities worldwide, leveraging DMS Pharmaceutical Group's established performance and comprehensive product portfolio to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DU26F0V17?
SPE2DU26F0V17 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 3, 2026.
How much is contract SPE2DU26F0V17 worth?
The government has obligated $1,758 on SPE2DU26F0V17.
Is contract SPE2DU26F0V17 an order under another contract?
Yes. SPE2DU26F0V17 is a delivery order under SPE2DU25D9811, an indefinite delivery contract.
Was contract SPE2DU26F0V17 competed?
The extent of competition for SPE2DU26F0V17 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award